These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
426 related items for PubMed ID: 28086831
1. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines. Ayyagari VN, Hsieh TJ, Diaz-Sylvester PL, Brard L. BMC Cancer; 2017 Jan 13; 17(1):49. PubMed ID: 28086831 [Abstract] [Full Text] [Related]
2. Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines. Ayyagari VN, Diaz-Sylvester PL, Hsieh TJ, Brard L. PLoS One; 2017 Jan 13; 12(9):e0185111. PubMed ID: 28931042 [Abstract] [Full Text] [Related]
3. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action. Ayyagari VN, Brard L. BMC Cancer; 2014 Feb 04; 14():61. PubMed ID: 24495391 [Abstract] [Full Text] [Related]
4. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. Yang YI, Kim JH, Lee KT, Choi JH. Gynecol Oncol; 2011 Dec 04; 123(3):588-96. PubMed ID: 21945308 [Abstract] [Full Text] [Related]
6. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells. Dasari VR, Carey DJ, Gogoi R. BMC Cancer; 2020 Apr 03; 20(1):273. PubMed ID: 32245422 [Abstract] [Full Text] [Related]
7. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS. Cancer Res; 1999 May 15; 59(10):2425-32. PubMed ID: 10344753 [Abstract] [Full Text] [Related]
8. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways. Shen W, Liang B, Yin J, Li X, Cheng J. Cell Biochem Biophys; 2015 May 15; 72(1):203-13. PubMed ID: 25510462 [Abstract] [Full Text] [Related]
9. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Gynecol Oncol; 2001 Jun 15; 81(3):380-90. PubMed ID: 11371126 [Abstract] [Full Text] [Related]
10. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, Liao W, Bast RC, Lu Z. Cell Death Dis; 2015 Aug 06; 6(8):e1836. PubMed ID: 26247722 [Abstract] [Full Text] [Related]
11. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer. Casagrande N, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D. Clin Cancer Res; 2014 Nov 01; 20(21):5496-506. PubMed ID: 25231401 [Abstract] [Full Text] [Related]